ERBB2 and breast cancer: There also appears to be an association between germline TP53 mutations and human epidermal growth factor receptor 2 (HER2)–positive breast cancer (Melhem-Bertrandt et al., 2011; NCCN, 2017; Wilson et al., 2010).